This company has been acquired
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
DICE Overzicht aandelen
DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas.
| Sneeuwvlok Score | |
|---|---|
| Waardering | 0/6 |
| Toekomstige groei | 0/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 0/6 |
DICE Therapeutics, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$47.55 |
| 52 Week Hoogtepunt | US$47.90 |
| 52 Week Laag | US$15.08 |
| Bèta | 0 |
| 11 maand verandering | 1.67% |
| 3 maanden verandering | 32.90% |
| 1 Jaar Verandering | 131.16% |
| 33 jaar verandering | n/a |
| 5 jaar verandering | n/a |
| Verandering sinds IPO | 28.90% |
Recent nieuws en updates
Recent updates
We're Not Very Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Rate
May 14
DICE Therapeutics positive phase 1 data for psoriasis candidate leads shares 71% higher
Oct 11Here's Why We're Not Too Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Situation
Sep 11DICE Therapeutics GAAP EPS of -$0.58
Aug 11DICE Therapeutics initiated at buy at Wainwright on platform for small molecule drugs
Jul 18Rendement voor aandeelhouders
| DICE | US Pharmaceuticals | US Markt | |
|---|---|---|---|
| 7D | 0.2% | 0.2% | 0.8% |
| 1Y | 131.2% | 23.5% | 38.4% |
Rendement versus industrie: DICE exceeded the US Pharmaceuticals industry which returned 7.3% over the past year.
Rendement versus markt: DICE exceeded the US Market which returned 4.8% over the past year.
Prijsvolatiliteit
| DICE volatility | |
|---|---|
| DICE Average Weekly Movement | 11.3% |
| Pharmaceuticals Industry Average Movement | 9.4% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stabiele aandelenkoers: DICE's share price has been volatile over the past 3 months.
Volatiliteit in de loop van de tijd: DICE's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2013 | 81 | J. Judice | www.dicetherapeutics.com |
DICE Therapeutics, Inc. Samenvatting
| DICE fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$2.27b |
| Inkomsten(TTM) | -US$104.24m |
| Inkomsten(TTM) | n/a |
0.0x
P/S-verhouding-21.8x
Koers/WinstverhoudingIs DICE overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| DICE resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$0 |
| Kosten van inkomsten | US$62.56m |
| Brutowinst | -US$62.56m |
| Overige uitgaven | US$41.68m |
| Inkomsten | -US$104.24m |
Laatst gerapporteerde inkomsten
Jun 30, 2023
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -2.18 |
| Brutomarge | 0.00% |
| Nettowinstmarge | 0.00% |
| Schuld/Eigen Vermogen Verhouding | 0% |
Hoe presteerde DICE op de lange termijn?
Bekijk historische prestaties en vergelijking